Table 1.
Summary of case reports of primary squamous cell carcinoma published between 2018 and 2023.
| Author | Age/Gender | Tumor Location | Treatment | Response |
|---|---|---|---|---|
| Farokhi et al. (8) | 57/M | Pancreatic head and liver metastasis | Leucovorin, fluorouracil, and irinotecan hydrochloride | 1 month progression-free disease |
| Majumdar et al. (9) | 60/M | Pancreatic tail | Neoadjuvant Gemcitabine and nanosomal paclitaxel lipid suspension with a pancreatico-splenectomy | 2 months progression-free disease |
| Li et al. (10) | 70/F | Pancreatic body | Laproscopic distal pancreatectomy and splenectomy | 6 months progression-free disease |
| Alajlan et al. (11) | 79/M | Pancreatic tail with invasion into splenic hilum and stomach body | “ palliative chemotherapy” | 3 months overall survival |
| Yang et al. (12) | 54/F | Pancreatic neck | Sintilimab and Gemcitabine | 4 months progression-free survival |
| Zhang et al. (6) | 64/F | Pancreatic tail with LN metastasis | Intensity-modulated radiation therapy with paclitaxel, cisplatin, and gemcitabine | 8 months overall survival |
| Huang et al. (13) | 52/F | Pancreatic tail with hepatic and LN metastases | Albumin-bound paclitaxel and cisplatin | 13 months progression-free disease |
| Grant et al. | 65/M | Pancreatic head with LN metastases | Gemcitabine, cisplatin, and nab-paclitaxel | Complete pathologic response without recurrence |